American Chemical Society recognizes Model Medicines’ MDL-001 among next generation of COVID-19 antivirals

Analyst Coverage
Written By Lani Nguyen

Model Medicines is honored to have our oral, pan-antiviral therapeutic, MDL-001, highlighted as a potential next generation, best-in-class COVID-19 therapeutic in an article in the American Chemical Society's C&EN.

Lani Nguyen
Previous

Model Medicines to Participate in the Berenberg Discover AI Seminar 2022
Next

Model Medicines to Participate in the Truist Securities Life Sciences AI Symposium